Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain
Authors:
- Fernando Fernández-SánchezFFFernando Fernández-Sánchez
- Nuria Fernández-MorenoNFNuria Fernández-Moreno
- Antonio José Hervas-MolinaAHAntonio José Hervas-Molina
- Francisco Casado-CaballeroFCFrancisco Casado-Caballero
- Juan Jesús Puente-GutierrezJPJuan Jesús Puente-Gutierrez
- Hector Pallares-ManriqueHPHector Pallares-Manrique
- Claudio Rodríguez-RamosCRClaudio Rodríguez-Ramos
- Clotilde Fernández-GutierrezCFClotilde Fernández-Gutierrez
- Angeles Pérez-AisaAPAngeles Pérez-Aisa
- Francisco Rivas-RuizFRFrancisco Rivas-Ruiz
- Natalia Montiel Quezel-GuerrazNQNatalia Montiel Quezel-Guerraz
- 30 July 2015
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 92 (2) , 78-82
Abstract
Background: The eradication of Helicobacter pylori (HP) using clarithromycin (CLA)-based triple therapy depends on the resistance of HP to antibiotics. The Maastricht III conference recommends the implementation of locoregional surveillance programmes for primary resistance of HP to CLA. In Andalusia, there are no previous data in this respect. The aim of this study was to determine the prevalence of the primary resistance of HP to CLA and levofloxacin (LF) in southern Spain. Methods: Multicentre cross sectional study was carried out in 6 hospitals in Andalusia. Patients of both sexes numbering 401 were included (male 48%), aged 18-80 years and naïve to HP eradication. Resistance of HP to CLA (CLAr) and LF (LFr) was assessed by determining mutations by PCR: mutations of the 23S rRNA gene define CLAr and mutations of the gene gyrA define LFr. Four hundred one gastric samples were collected. CLAr was detected in 72 patients (17.9%) and LFr was detected in 56 patients (13.9%). Heteroresistance was detected for both antibiotics: CLA 37/72 (51.3%) and LF 28/56 (50%). Variability for CLAr was detected among the centres, ranging from 11.5% to 24.7% without statistical significance (p = 0.12). Female sex was related to CLAr. Conclusions: In Andalusia, there is a high rate of primary CLAr and LFr. CLA-based triple therapy should be avoided as the primary eradication regimen in this region. There is a wide variability in the rate of CLAr among centres.Keywords
This publication has 18 references indexed in Scilit:
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997–2009)Journal of Antimicrobial Chemotherapy, 2011
- Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limitsJournal of Antimicrobial Chemotherapy, 2009
- Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance inHelicobacter pyloriJournal of Clinical Microbiology, 2009
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failureAlimentary Pharmacology & Therapeutics, 2005
- Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patientsJournal of Antimicrobial Chemotherapy, 2005
- Singleand Double Mutations in gyrA but Not in gyrB AreAssociated with Low- and High-Level Fluoroquinolone Resistance in HelicobacterpyloriAntimicrobial Agents and Chemotherapy, 2003
- New Site of Modification of 23S rRNA Associated with Clarithromycin Resistance of Helicobacter pylori Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2002